Rua Bioscience has recently unveiled a groundbreaking product derived from the legacy genetics of New Zealand’s black market era. This launch marks a significant milestone for the company, as it leverages decades of illicit expertise to create a premium medicinal cannabis product. The new product, a dried flower called Rua Rau Hiwa, is set to make waves in the competitive Australian market, which is one of the largest medicinal cannabis markets globally.
A Milestone in Medicinal Cannabis
Rua Bioscience’s new product launch is a testament to the company’s commitment to innovation and quality. The dried flower, Rua Rau Hiwa, is sourced from unique cannabis strains developed over generations in New Zealand. These strains have been cultivated and perfected in Rua’s facility in Mangaoporo, Tairawhiti. The product’s introduction to the Australian market signifies the company’s successful expansion and its ability to meet the high standards of international markets.
The Australian medicinal cannabis market is valued at approximately $450 million, with over 300 prescribers and a rapidly growing patient base. Rua Bioscience’s entry into this market is a strategic move that positions the company for further growth and success. The company’s focus on research and development, coupled with its legacy genetics, gives it a competitive edge in the global cannabis industry.
Rua Bioscience’s Chief Executive, Paul Naske, emphasized the importance of this launch, stating that it fulfills the company’s commercial model focused on genetics and international distribution. The company’s ability to offer premium cannabis genetics to thousands of patients across Australia is a significant achievement and a step towards its goal of becoming a global leader in the medicinal cannabis industry.
Leveraging Legacy Genetics
The legacy genetics used in Rua Rau Hiwa are a result of decades of illicit cultivation and expertise in New Zealand. These genetics have been developed and refined by growers who have a deep understanding of cannabis plant genetics and their medicinal properties. Rua Bioscience has harnessed this expertise and combined it with scientific research to create a product that meets the highest standards of quality and efficacy.
The company’s facility in Mangaoporo, Tairawhiti, is home to these unique cannabis strains. The facility’s state-of-the-art technology and rigorous quality control measures ensure that each batch of Rua Rau Hiwa is consistent and effective. This commitment to quality is what sets Rua Bioscience apart from its competitors and makes its products highly sought after in the medicinal cannabis market.
Rua Bioscience’s focus on legacy genetics is not just about leveraging past expertise; it is also about preserving and honoring the heritage of New Zealand’s cannabis growers. By bringing these genetics to the international market, the company is showcasing the unique qualities of New Zealand cannabis and establishing itself as a leader in the global industry.
Expanding Global Reach
With the successful launch of Rua Rau Hiwa in Australia, Rua Bioscience is now setting its sights on other international markets. The company plans to introduce its New Zealand genetics to the German market next year, further expanding its global footprint. Germany is another significant market for medicinal cannabis, and Rua Bioscience’s entry into this market will further solidify its position as a global leader.
The company’s strategy involves building strong distribution networks and partnerships in each market it enters. In Australia, Rua Bioscience has already established four distributors, with one covering 50% of the market. This extensive distribution network ensures that Rua Rau Hiwa reaches a wide range of patients and meets diverse needs and price points.
Rua Bioscience’s international expansion is driven by its commitment to providing high-quality medicinal cannabis products to patients worldwide. The company’s focus on research and development, coupled with its legacy genetics, positions it for continued success and growth in the global market. As Rua Bioscience continues to expand, it remains dedicated to its mission of improving patient outcomes through innovative and effective medicinal cannabis products.
